Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $90.2 million.

  • aTYR PHARMA's Cash & Current Investments rose 3669.66% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.2 million, marking a year-over-year increase of 3669.66%. This contributed to the annual value of $72.1 million for FY2024, which is 2652.75% down from last year.
  • Per aTYR PHARMA's latest filing, its Cash & Current Investments stood at $90.2 million for Q3 2025, which was up 3669.66% from $80.3 million recorded in Q2 2025.
  • aTYR PHARMA's 5-year Cash & Current Investments high stood at $116.4 million for Q3 2021, and its period low was $44.1 million during Q2 2021.
  • In the last 5 years, aTYR PHARMA's Cash & Current Investments had a median value of $84.5 million in 2024 and averaged $85.3 million.
  • As far as peak fluctuations go, aTYR PHARMA's Cash & Current Investments surged by 24053.14% in 2021, and later crashed by 3870.32% in 2022.
  • Over the past 5 years, aTYR PHARMA's Cash & Current Investments (Quarter) stood at $107.9 million in 2021, then crashed by 38.7% to $66.1 million in 2022, then skyrocketed by 48.41% to $98.2 million in 2023, then fell by 26.53% to $72.1 million in 2024, then rose by 25.06% to $90.2 million in 2025.
  • Its Cash & Current Investments was $90.2 million in Q3 2025, compared to $80.3 million in Q2 2025 and $76.3 million in Q1 2025.